IncRNA MALAT1, HOTTIP and PVT1 as predictors for predicting the efficacy of GEM based chemotherapy in first-line treatment of pancreatic cancer patients

Cui-Juan Wang¹, Sheng-Bin Shi², Jing Tian², Jun Xu² and Zuo-Xing Niu²

¹Shandong University of Traditional Chinese Medicine, Jinan, P.R. China
²Department of Medical Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, P.R. China
³Central Laboratory, Shandong Academy of Occupational Health Medicine, Jinan, P.R. China

*These authors have contributed equally to this work

Correspondence to: Zuo-Xing Niu, email: nzx6677@163.com

Keywords: advanced pancreatic cancer; GEM based chemotherapy; first-line therapy; IncRNA MALAT1; HOTTIP and PVT1

ABSTRACT

This study evaluated the Inc-RNAs as biomarker to predict efficacy of gemcitabine (GEM) based chemotherapy as the first-line treatment for locally advanced or advanced pancreatic cancer patients. We selected 62 patients with GEM based chemotherapy and divided two groups according to the PFS. We found that the expression of MALAT1, HOTTIP, and PVT1 in serum had a significant difference among the two groups. Furthermore, we estimated the PFS and response rate based on the expression levels of MALAT1, HOTTIP and PVT1. The response rate of two groups showed a significant difference according to the expression levels of MALAT1, HOTTIP and PVT1. Based on the expression levels of MALAT1, HOTTIP and PVT1, the response rate of high expression of PVT1 and low expression of PVT1 was respectively 14.8% and 37.1% and 18.2% (high HOTTIP group) and 37.9% (low HOTTIP group), 10.7%(high MALAT1 group) and 41.1% (low MALAT1 group). The PFS of patients with high and low expression levels PVT1 was 2.6 months and 4.0 months (p<0.001), respectively. The PFS of patients with high and low expression levels of HOTTIP was 2.7 months and 4.1 months (p<0.001), respectively, and the PFS of patients with high and low expression levels of MALAT1 was 3.0 months and 3.7 months (P=0.026), respectively. The results suggest that MALAT1, HOTTIP and PVT1 as predictors to predict the efficacy of GEM based chemotherapy in first-line treatment of pancreatic cancer patients.

INTRODUCTION

Pancreatic cancer is one of the most aggressive cancers with a high mortality rate in the world [1]. Despite the efforts of surgery, chemotherapy and radiation, the five-year survival rate is still less 5% and median survival time is about 4-6 months [2]. Because of early metastasis and resistant to chemotherapy and radiation therapy [3]. Due to lack of specific early symptoms, most patients appear an advanced stage of disease at the time of diagnosis. For patients with advanced stage, chemotherapy plays an important role. Although the development of chemotherapy, gemcitabine-based therapy remains the standard first line treatment [4]. To date, carbohydrate antigen 19–9 (CA19-9) has certain role to predict the efficacy, but the specificity and sensitivity are very low [5]. Therefore, it is urgent to search for a sensitive biomarker to predict the efficacy of gemcitabine-based therapy.
Long non-coding RNAs (lncRNA) are a class of noncoding RNA with more than 200 nucleotides, but lack protein coding capacity [6, 7]. More and more investigations have demonstrated that lncRNAs exert an important role in proliferation, apoptosis and migration. The expression levels of certain lncRNAs are associated with cancer recurrence, cancer progression, metastasis, and poor prognosis [8-10]. Some studies have reported that some lncRNAs such as H19, HOTAIR, HOTTIP, MALAT1, PVT1, ENST0000048073, Gas5, AF339813, LOC389641, AFAP1-AS1, BC008363, GAS, HMlincRNA717, HOTAIRM1, HULU [11-19] are most closely associated with PC. Therefore, lncRNAs might help to provide novel potential molecular markers for predicting the efficacy of gemcitabine-based.

Some studies shown that lncRNAs can be readily detected by qPCR from the body fluids, i.e. serum, plasma, gastric liquids, or urine [20]. In our study, we evaluated the levels of some lnc-RNAs in peripheral blood of patients with pancreatic cancer and analysed the correlation between lnc-RNAs, Progression-Free-Survival (PFS) and Response rate.

RESULTS

Patient characteristics

In our study, all patients were histologically diagnosed with pancreatic adenocarcinoma and were classified as locally advanced or advanced pancreatic cancer by CT. Total 62 patients received the GEM based chemotherapy as first-line treatment. According to the PFS, we divided into less than three months groups of PFS (29 patients) and greater than three months groups of PFS (33 patients). The two group patients have no significant difference in sex, age, phase and chemotherapy regimens. The characteristics of the two group patients are summarized in Table 1.

| Factor                        | PFS≤ 3 months groups | PFS>3 months groups | P   |
|-------------------------------|----------------------|---------------------|-----|
| Median age (range)            | 56.5 (37–68)         | 59.0 (36–69)        |     |
| Gender                        |                      |                     | 0.62|
| Male                          | 18                   | 14                  |     |
| Female                        | 15                   | 15                  |     |
| Performance status            |                      |                     | 0.40|
| 0-1                           | 17                   | 18                  |     |
| 2                             | 16                   | 11                  |     |
| First line regimen            |                      |                     | 0.38|
| Gemcitabine/Cisplatin         | 11                   | 13                  |     |
| Gemcitabine/Nab-paclitaxel    | 6                    | 8                   |     |
| Gemcitabine/Oxaliplatin       | 15                   | 9                   | 0.66|
| Clinical stage                |                      |                     |     |
| III                           | 12                   | 9                   |     |
| IV                            | 21                   | 20                  |     |
| Tumor location                |                      |                     | 0.60|
| Head                          | 23                   | 20                  |     |
| Body                          | 7                    | 8                   |     |
| Tail                          | 3                    | 1                   |     |
| Differentiation               |                      |                     | 0.47|
| Well                          | 19                   | 15                  |     |
| Moderate                      | 8                    | 5                   |     |
| Poor                          | 6                    | 9                   |     |

Table 1: Patients’ characteristics
In the two groups, the expression levels of three lnc-RNAs (MALAT1, HOTTIP, PVT1) had a significant difference (Table 2). Furthermore, we divided patients into high and low expression levels of lncRNAs groups based the MALAT1, HOTTIP, PVT1. The response rate of two groups showed a significant difference according to the expression levels of MALAT1, HOTTIP, PVT1. The response rate of high expression of PVT1 and low expression of PVT1 was respectively 14.8% and 37.1% and had a significant difference (Table 3). Based on the expression level of HOTTIP, MALAT1, the response rate of high expression of PVT1 and low expression of PVT1 was respectively 14.8% and 37.1% and had a significant difference (Table 3). Based on the expression level of HOTTIP, MALAT1, the response rate was respectively 18.2% (high HOTTIP group) and 37.9% (low HOTTIP group) and 41.1% (high MALAT1 group) and 37.1% (low MALAT1 group) (Tables 4 and 5).

According to the expression levels of PVT1, MALAT1, HOTTIP, the PFS showed a significant difference. The PFS of patients with high and low expression levels PVT1 was 2.6 months (95% CI, 2.2-2.9) and 4.0 months (95% CI, 3.5-4.5) (p<0.001), respectively (Figure 1). The PFS of patients with high and low expression levels of HOTTIP was 2.7 months (95% CI, 2.3-3.1) and 4.1 months (95% CI, 3.6-4.7) (p<0.001), respectively, and the PFS of patients with high and low expression levels of MALAT1 was 3.0 months (95% CI, 2.6-3.3) and 3.7 months (95% CI, 3.2-4.3) (p=0.026), respectively (Figures 2 and 3).

**DISCUSSION**

At present, pancreatic cancer remains a highly malignant tumor and the prognosis is extremely poor. For many years, new drugs for cancer treatment have been appeared consecutively, but Gemcitabine-based treatment remained the first-line chemotherapy regimen for patients with advanced pancreatic cancer [21]. Although, the level of serum CA19-9 may help to predict the prognosis partly, the
The situation is unsatisfying the need of individualized therapy [22, 23]. Therefore, we have focused on searching reliable biomarkers to predict the therapeutic efficacy and avoid some ineffective patients to receive aggressive therapies.

LncRNAs were found to be more stable in that case situation of multiple freeze-thaw cycles, strong acid and base. Some studies have demonstrated that dysregulated expression of lncRNAs may independently predict patient outcome [24, 25]. Li et al. found that the expression of HOTTIP was up-regulated in pancreatic cancer tissues and demonstrated that HOTTIP was over-expressed in cancer tissues compared with non-tumoral tissues and elevated the ability of pancreatic cell proliferation and invasion. Targeted silencing of HOTTIP may enhance the antitumor effects of gemcitabine [12]. Furthermore, expression of HOTTIP has been identified as a negative prognostic

**Table 4: The difference of response according to the level of HOTTIP**

| Response | High HOTTIP (33) | Low HOTTIP (29) | P  |
|----------|------------------|-----------------|----|
| CR       | 0                | 0               |    |
| PR       | 6 (18.2%)        | 11 (37.9%)      |    |
| SD       | 7 (21.2%)        | 13 (44.8%)      |    |
| Response rate | 6 (18.2%)  | 11 (37.9%)      | <0.001 |
| Median PFS (95% CI) | 2.7 (2.3-3.1) months | 4.1 (3.6-4.7) months | <0.001 |

**Table 5: The difference of response according to the level of MALAT1**

| Response | High MALAT1 (28) | Low MALAT1 (34) | P  |
|----------|------------------|-----------------|----|
| CR       | 0                | 0               |    |
| PR       | 3 (10.7%)        | 14 (41.1%)      |    |
| SD       | 9 (32.1%)        | 16 (47.1%)      |    |
| Response rate | 3 (10.7%)  | 14 (41.1%)      | 0.007 |
| Median PFS (95% CI) | 3.0 (2.6-3.3) months | 3.7 (3.17-4.26) months | 0.026 |

Figure 1: Kaplan–Meier analysis for PFS in pancreatic cancer patients with High expression level of PVT1 and low expression level of PVT1. (P < 0.001).
factor in hepatocellular carcinoma patients [26]. Another study shows that HOTTIP increases pancreatic cancer cell proliferation, survival, and migration through HoxA family genes other than HoxA13 [27].

One study has shown that PVT1 gene could regulate Gemcitabine sensitivity in human pancreatic cell line. The sensitivity of Gemcitabine was changed according to the situation of antisense orientation and sense orientation of full length PVT1 cDNA. Overexpression of PVT1 decreased gemcitabine sensitivity, while functional inactivation of the PVT1 enhanced Gemcitabine sensitivity [28]. Mechanism study demonstrated that the upregulated PVT1 could induce cell cycle genes and activation of the TGFβ1 signaling pathway and PVT1 binds to EZH2, recruits EZH2 to the miR-200b promoter, which increases histone H3K27 trimethylation level on the miR-200b.
promoter, and inhibits miR-200b expression [29, 30]. Knockdown of MALAT1 expression inhibited PC cell proliferation, migration, and invasion in vitro by inducing G2/M cell cycle arrest, suppressing EMT and decreasing cancer stem-like properties [13, 31]. In our study, the high and low expression level of Inc-RNAs had a different PFS and response rate. Above studies may also provide a certain confirmation.

In conclusion, our study suggested that PVT1, HOTTIP, MALAT1 was associated with the efficacy of first-line treatment with GEM based chemotherapy in pancreatic cancer. They may be novel non-invasive biomarkers for predicting the efficacy. The limitation of our study was that the sample size was small and a larger sample size is needed to confirm the results in the future. In-depth analysis of their biological functions is needed.

MATERIALS AND METHODS

Patients

The patients who take part in this study had histologically proven advanced pancreatic cancer. All patients received GEM based chemotherapy in first-line treatment between February 2014 and January 2016 at Shandong Tumor Hospital. The patient selection criteria were: age, 18–75 years old; ECOG performance status (PS) ≤2; adequate hematological, hepatic function adrenal functions (white blood cell count ≥4.0×10⁹/l; neutrophil count ≥1.5×10⁹/l; platelet count ≥100×10⁹/l and hemoglobin ≥10 g/dl; ALT and AST ≤ 2.5 × upper limits of normal; total bilirubin ≤1.5× upper limits of normal; creatinine clearance ≥ 60 ml/min or creatinine ≤ upper limits of normal); and life expectancy greater than 3 months. All the patients had at least one measurable lesions by CT scan or MRI. Exclusion criteria were massive pleural effusion or ascites, active concomitant malignancy, brain metastasis, pregnant or lactating if patients were women. All the patients were informed, and the trial was authorized by the ethics committee of Shandong tumor hospital.

Detection serum levels of lncRNAs

Blood samples were collected before chemotherapy and then centrifuged at 3000 × g for 10 min, and stored in RNase- and DNase-free tubes at –80 °C before use. Serum RNA isolation was performed using a Blood Total RNA Isolation Kit (RP4001, BioTeke, Beijing, China) according to manufacturer’s protocol. RT and qPCR kits were used to evaluate the expression levels of the selected lncRNAs in the samples as described previously [32]. β-actin was used as control. The relative expression levels of each lncRNA was calculated using the 2^−ΔΔCt method and was normalized to that of β-actin.

Treatment and evaluation

All patients received GEM based chemotherapy, including gemcitabine plus cisplatin, gemcitabine plus Nab-paclitaxel or gemcitabine plus Oxaliplatin. The dosages were described previously [33, 34]. Treatment continued until a maximum of 6 cycles, progressive disease, unacceptable toxicity occurred, or withdrawal of patient consent. Before treatment, all patients were collected blood to test the level of serum IncRNAs and carbohydrate antigen (CA) 19-9(CA19-9). Tumor responses were evaluated every two cycles of treatment via computed tomography (CT) according to the Response Evaluation Criteria in Solid Tumors (RECIST, ver. 1.1).

Statistical analysis

All statistical analyses were performed using the SPSS 17.0 software package (SPSS Inc., Chicago, IL, USA). The correlations were analyzed using the Student’s t-test, the Chi-square test and analysis of variance (ANOVA). Survival curves were analyzed according to the Kaplan-Meier method. All statistical tests were two tailed and results with P = 0.05 were defined as statistically significant.

Abbreviations

GEM, gemcitabine; CA19-9, carbohydrate antigen; lncRNA, long non-coding RNAs; PFS, progression-free-survival; PS, performance status; CT, computed tomography; RECIST, response evaluation criteria in solid tumors.

ACKNOWLEDGMENTS

Not applicable.

CONFLICTS OF INTEREST

No author has any conflicts of interest to declare.

FINANCIAL SUPPORT

This work was supported by grants from Shandong Medicine and Health Science. Technology Project (2015WS0165) and key research and development plan of Shandong province (No. 2016GSF201142).

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.
of pancreatic ductal adenocarcinoma and increases cell invasion by regulating E-cadherin in a TNFRSF10A-related manner. Cancer Lett. 2016;371:354–65.

18. Huang X, Zhi X, Gao Y, Ta N, Jiang H, Zheng J. lncRNAs in pancreatic cancer. Oncotarget. 2016;7:57379–90. https://doi.org/10.18632/oncotarget.10545.

19. Hu P, Shangguan J, Zhang L. Downregulation of NUF2 inhibits tumor growth and induces apoptosis by regulating lncRNA AF339813. Int J Clin Exp Pathol. 2015;8:2638–48.

20. Kladi-Skandali A, Michaelidou K, Scorilas A, Mavridis K. Long noncoding RNAs in digestive system malignancies: A novel class of cancer biomarkers and therapeutic targets? Gastroenterol Res Pract. 2015;2015:319861.

21. Burriss HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Stormiolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–13.

22. De La Cruz MS, Young AP, Ruffin MT. Diagnosis and management of pancreatic cancer. Am Fam Physician. 2014;89:626–32.

23. Ren YQ, Zhang HY, Su T, Wang XH, Zhang L. Clinical significance of serum survivin in patients with pancreatic ductal adenocarcinoma. Eur Rev Med Pharmacol Sci. 2014;18:3063–8.

24. Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, Brenner JC, Laxman B, Asangani IA, Grasso CS, Kominsky HD, Cao X, Jing X, Wang X, et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol. 2011;29:742–9.

25. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, Wang Y, Brzoska P, Kong B. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464:1071–6.

26. Quagliata L, Matter MS, Piscuoglio S, Arabi L, Ruiz C, Procino A, Kovac M, Moretti F, Makowska Z, Boldanova T, Andersen JB, Hämerle M, Tornillo L. Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. Hепatology. 2014;59:911–23.

27. Cheng Y, Jutooru I, Chadalapaka G, Corton JC, Safe S. The long non-coding RNA HOTTIP enhances pancreatic cancer cell proliferation, survival and migration. Oncotarget. 2015;6:10840–52. https://doi.org/10.18632/oncotarget.3450.

28. You L, Chang D, Du HZ, Zhao YP. Genome-wide screen identifies PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cells. Biochem Biophys Res Commun. 2011;407:1–6.
29. Zhang S, Zhang G, Liu J. Long noncoding RNA PVT1 promotes cervical cancer progression through epigenetically silencing miR-200b. APMIS. 2016;124:649–58.
30. Wang F, Yuan JH, Wang SB, Yang F, Yuan SX, Ye C, Yang N, Zhou WP, Li WL, Li W, Sun SH. Oncofetal long noncoding RNA PVT1 promotes proliferation and stem cell-like property of hepatocellular carcinoma cells by stabilizing NOP2. Hepatology. 2014;60:1278–90.
31. Pang EJ, Yang R, Fu XB, Liu YF. Overexpression of long noncoding RNA MALAT1 is correlated with clinical progression and unfavorable prognosis in pancreatic cancer. Tumour Biol. 2015;36:2403–7.
32. Wu Y, Wang YQ, Weng WW, Zhang QY, Yang XQ, Gan HL, Yang YS, Zhang PP, Sun MH, Xu MD, Wang CF. A serum-circulating long noncoding RNA signature can discriminate between patients with clear cell renal cell carcinoma and healthy controls. Oncogenesis. 2016;5:e192.
33. De Vita F, Ventriglia J, Febbraro A, Laterza MM, Fabozzi A, Savastano B, Petrillo A, Diana A, Giordano G, Troiani T, Conzo G, Galizia G, Ciardiello F, Orditura M. NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice. BMC Cancer. 2016;16:709.
34. Leone F, Gatti M, Massucco P, Colombi F, Sperti E, Campanella D, Regge D, Gabriele P, Capussotti L, Aglietta M. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience. Cancer. 2013;119:277–84.